Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

The SOUL trial compared oral semaglutide vs. placebo on top of standard care in patients with type 2 diabetes and ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Hollywood exec sheds 82 pounds at SinoUnited Health’s new Shanghai center—where science, AI, and expert care redefine weight ...

Successfully treating type 2 diabetes may involve focusing on brain neurons, rather than simply concentrating on obesity or insulin resistance, according to a study published today in the Journal of ...

Some women may be unaware they're living with risks for heart disease, kidney disease and metabolic conditions like diabetes, ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

Millions of women may be unknowingly living with risk factors for heart, kidney and metabolic disease – interconnected conditions that together drive risk for cardiovascular disease, the leading cause ...